national stem-cell therapy logo

BlueRock’s Phase I Study with Bemdaneprocel in Parkinson’s Disease Patients Achieves Main Goal

BlueRock Therapeutics

BlueRock Therapeutics, in collaboration with Bayer AG, recently announced the successful results of their Phase I clinical trial for bemdaneprocel (BRT-DA01), an innovative cellular therapy derived from stem cells, aimed at treating Parkinson’s disease. The findings were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Key Highlights: Dr. Claire […]